Engineered Bacterium Oncolytic Microbe Pipeline — PatSnap Eureka
Engineered Bacterium & Oncolytic Microbe Pipeline: Solid Tumors & IBD
Bacteria-based cancer therapy and oncolytic microbe platforms are rapidly expanding, driven by the intrinsic tropism of anaerobic bacteria for hypoxic solid tumor microenvironments and the capacity of oncolytic viruses to selectively lyse tumor cells while stimulating anti-tumor immunity.
Solid Tumors, IBD, and the Hypoxic Tumor Core
Retrieved results highlight solid tumors — including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma, melanoma, sarcoma, glioblastoma, hepatocellular carcinoma, and lung cancer — as the primary disease contexts addressed across the dataset. The defining pathological feature exploited by these therapies is the hypoxic, necrotic tumor core, characterized by anomalous vascularization, acidity, and immune evasion.
This microenvironment simultaneously confounds conventional chemotherapy and radiotherapy while attracting obligate and facultative anaerobic bacteria — the foundational mechanism enabling tumor-selective colonization. Research from NIH-affiliated institutions and independent groups consistently identifies this tropism as the key selectivity driver.
IBD-directed engineered microbe platforms represent an adjacent and growing application. Commensal bacteria engineered for intestinal cytokine delivery — targeting TNF-α, IL-22, and IL-2 — bridge the oncology and gastroenterology application spaces. The PatSnap life sciences intelligence platform covers both oncology and IBD pipeline signals in a unified patent and literature dataset.
Molecular targets addressed across the dataset include the PD-1/PD-L1 axis, STING pathway, CD47 "don't eat me" signal, CXCL16 chemokine axis, TNF-α/IL-22/IL-2 cytokine circuits, and intratumoral hypoxia signaling with prodrug-converting enzyme (PCE) systems — particularly relevant for Clostridium-based platforms. The European Patent Office has seen active filings across multiple assignees in this space.
Eight Engineered Microbe Platforms Across Oncology & IBD
From attenuated Salmonella to oncolytic Newcastle Disease Virus, each platform exploits a distinct biological mechanism to selectively target tumor microenvironments or intestinal inflammation.
Salmonella typhimurium — Attenuated & Engineered
The most extensively cited bacterial modality in the dataset. Attenuated strains include VNP20009 (msbB/purI deletion), A1-R (leucine/arginine auxotroph), SL7207, and ZnuABC transporter-deficient mutants. Mechanisms include direct tumor cytotoxicity, innate immune activation via LPS and flagellin (PAMPs), and delivery of cytokines, siRNA, and prodrug-converting enzymes. VNP20009 reached Phase I clinical trial in metastatic melanoma and squamous cell carcinoma — the most advanced bacterial cancer therapy clinical dataset retrieved. A1-R has been tested in PDOX models across 10+ tumor types by AntiCancer, Inc.
Phase I Clinical (VNP20009)Clostridium novyi-NT & C. ghonii
Obligate anaerobes exploiting the strictly hypoxic, necrotic tumor core. C. novyi-NT (attenuated via alpha-toxin gene deletion) is the most studied species. A novel derivative of Clostridium ghonii, developed at Griffith University (active EP patent, 2018), targets colon and head-and-neck cancer xenograft models. Mechanisms include spore germination in hypoxic zones, direct oncolysis, immune cell recruitment, and prodrug activation via the NmeNTR nitroreductase/CB1954 system — a critical advance over prior nitroreductase PCEs with insufficient activity at clinically achievable serum concentrations.
Preclinical / Early-phaseE. coli Nissle 1917 (EcN) — Engineered Microrobot
EcN is heavily represented as a chassis for synthetic biology-based cancer therapy. Applications include neoantigen peptide array delivery for cancer vaccination, checkpoint nanobody production with lysis-circuit-controlled release, STING agonist (cyclic dinucleotide) production as SYNB1891, CXCL16-mediated T cell recruitment, cytolysin A expression driven by tumor acidity, and NIR/photothermal-controlled PD-1 inhibitor expression. For IBD, PROT3EcT (University of Bonn) uses a modified Type 3 secretion system to secrete TNFα-neutralizing nanobodies, demonstrating colitis prevention in a single prophylactic dose. SYNB1891 is designed to meet manufacturability and regulatory requirements with built-in biocontainment features.
IND-enabling (SYNB1891)Newcastle Disease Virus (NDV)
NDV is the most extensively covered oncolytic virus modality in retrieved results. As an avian paramyxovirus, NDV preferentially replicates in human tumor cells due to defects in interferon signaling in many cancers, while sparing normal cells. Retrieved results describe wild-type isolates, recombinant NDV expressing IL-2 or IFNβ, multi-basic cleavage site (MBCS) fusion protein variants, and NDV combined with dendritic cell (DC) vaccines and bi-specific antibodies. IOZK Cologne summarizes 60 years of clinical evaluation and achieved GMP production in 2015. Pancreatic and gastrointestinal adenocarcinomas are particularly highlighted in Erasmus MC studies.
Phase I/II Clinical (GMP achieved)Bifidobacterium — In Situ Delivery Platform
Bifidobacterium species (obligate anaerobes, non-pathogenic) are described for in situ delivery and production (iDPS) of anti-cancer molecules exploiting tumor hypoxia. Bifidobacterium breve demonstrates strain-specific enhancement of PD-1 blockade and oxaliplatin efficacy in MC38 colon carcinoma models (GIST, 2021). A sonodynamic therapy application conjugates clinical sonosensitizer HMME to Bifidobacterium longum (BiL), combined with STING agonist SR717, demonstrating additive tumor eradication in primary and metastatic settings.
PreclinicalLactobacillus reuteri & Lactococcus lactis GEN3013
Lactobacillus reuteri is engineered to secrete biologically active human IL-22 (hIL-22), targeting intestinal inflammation for IBD applications (Baylor College of Medicine, 2020). Lactococcus lactis GEN3013 is reported to inhibit tumor angiogenesis and augment oxaliplatin and PD-1 blockade efficacy in murine models (GIST, 2022). Both are at the preclinical stage. The PatSnap chemicals and materials platform provides complementary formulation intelligence for live biotherapeutic delivery systems.
Preclinical (IBD & CRC)Pipeline Data: Targets, Modalities & IP Landscape
Visualised signals from patent filings and academic literature retrieved via PatSnap Eureka across engineered bacterium and oncolytic microbe platforms.
Molecular Targets Addressed by Platform Type
Distribution of molecular targets across engineered bacterium and oncolytic virus platforms in the retrieved dataset, from PD-1/PD-L1 to prodrug-converting enzyme systems.
IP Assignee Landscape: Academic vs. Commercial
Innovation activity is predominantly literature-driven from academic institutions, with a minority of active patent filings from commercial biotech entities including Synlogic, City of Hope, and Suzhou Prajna Biotech.
Clinical & Translational Readiness Signals
Key translational milestones identified in the dataset, from Phase I clinical data (Salmonella VNP20009) through IND-enabling work (SYNB1891) to preclinical IBD signals (PROT3EcT).
Active Patent Filings: Key Assignees & Jurisdictions
| Assignee | Platform / Modality | Jurisdiction | Year | Status |
|---|---|---|---|---|
| Synlogic Operating Company | EcN programmed for STING activation, anti-CD47, immunomodulators | IL (×3 patents) | 2019 | Pending |
| City of Hope | Bacterial cell + tumor-penetrating agent combination (PDAC) | EP | 2020 | Active |
| Griffith University | Oncolytic Clostridium ghonii strains — colon & head-and-neck cancer | EP | 2018 | Active |
| University of Basel | Recombinant virulence-attenuated Gram-negative strains — solid tumors | EP / IL (×2) | 2018–2021 | Active |
| Suzhou Prajna Biotech | Gut microbiota + oncolytic virus combination; biomarker-guided responder selection | JP | 2022 | Pending |
| Columbia University | EcN neoantigen vaccine delivery, checkpoint nanobody lysis circuits, CXCL16 T cell recruitment | Academic papers | 2019–2023 | Paper-driven |
| AntiCancer, Inc. | Salmonella A1-R PDOX models across 10+ tumor types | Academic papers | 2019 | Preclinical |
Map the competitive IP landscape for engineered microbe therapeutics
PatSnap Eureka connects patent filings, literature, and clinical signals in a single AI-powered workspace for IP and R&D teams.
Emerging Directions: Synthetic Circuits, Combination Strategies & Translational Advances
Retrieved results from 2020–2023 consistently signal movement toward combination strategies as the primary development direction, driven by acknowledged clinical limitations of single-agent monotherapy.
Synthetic Genetic Circuits — NIR & Acidity Control
Hefei National Research Center describes programmatic control of bacterial lifestyle (planktonic → biofilm → lysis) via NIR light-responsive hierarchical genetic circuits, enabling spatiotemporal drug release in deep tissue. Separately, cytolysin A (ClyA) expressed by E. coli and triggered by tumor acidity disrupts tumor blood vessels and induces thrombosis, cutting off nutrient supply to tumor cells.
Bacteria + Immune Checkpoint Inhibitors
The most frequently described combination across the dataset. Synlogic patents claim bacteria producing arginine + anti-CD47 nanobodies ± systemic pembrolizumab/nivolumab. Bifidobacterium breve + PD-1 blockade and Lactococcus lactis GEN3013 + anti-PD-1 corroborate this direction in CRC models. The PatSnap analytics platform tracks combination therapy IP signals across jurisdictions.
Bacterial Outer Membrane Vesicles (OMVs) as Neoantigen Vectors
A retrieved paper from the National Center for Nanoscience and Technology (China) describes orally administered engineered bacteria that generate OMVs displaying tumor antigens via ClyA surface fusion, with expression controlled by an arabinose-inducible promoter. This approach bridges IBD and solid tumor vaccine modalities in a single oral delivery platform.
Bacteria + STING Agonists — Additive Innate Activation
Both SYNB1891 (endogenously producing STING-activating cyclic dinucleotide) and Bifidobacterium longum conjugated with sonosensitizer HMME + SR717 demonstrate enhanced innate immune activation beyond what bacteria achieve alone. SYNB1891 generates durable immunological memory in murine models and is designed with built-in biocontainment features for regulatory-grade manufacturing.
Engineered Bacterium & Oncolytic Microbe Therapeutics — key questions answered
The most extensively cited bacterial modality is Salmonella typhimurium, including attenuated strains VNP20009, A1-R, SL7207, and ZnuABC transporter-deficient mutants. Other key species include Clostridium novyi-NT, E. coli Nissle 1917 (EcN), Bifidobacterium, Listeria monocytogenes, Lactobacillus reuteri, and Lactococcus lactis.
The foundational mechanism across all anaerobic and facultative anaerobic bacterial modalities is hypoxia-inducible tumor tropism. The hypoxic, poorly vascularized tumor core is the selective niche. This is exploited both passively (spore germination, anaerobic replication) and actively (synthetic genetic circuits with hypoxia-responsive promoters). Tumors with low collagen and disorganized blood vessels support most rapid intratumoral bacterial growth.
SYNB1891 is an E. coli Nissle 1917-based engineered bacterium developed by Synlogic that activates the STING pathway in tumor-resident phagocytic antigen-presenting cells, generating durable immunological memory. The system is described as designed to meet manufacturability and regulatory requirements with built-in biocontainment features, signaling active IND-enabling work. Efficacy in murine models with immunological memory formation and robust activation of human APCs has been demonstrated.
Salmonella VNP20009 (msbB/purI-deleted) is documented as the most advanced bacterial cancer therapy clinical dataset, having completed a Phase I clinical trial in metastatic melanoma and squamous cell carcinoma. It showed safe targeting but demonstrated insufficient tumor regression and dose-dependent toxicity including sepsis risk. This trial outcome is acknowledged as a driver for next-generation engineered approaches. No retrieved results contain explicit descriptions of Phase II or Phase III clinical trial outcomes for the core bacterial therapy modalities.
Newcastle Disease Virus (NDV) is the most extensively covered oncolytic virus modality in retrieved results. Retrieved results also describe oncolytic adenoviruses for GI malignancies including colorectal, pancreatic, and gastric cancers, as well as glioblastoma. Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus, is referenced contextually as the first FDA-approved oncolytic virus for advanced melanoma, providing a regulatory benchmark for the broader field.
IBD-directed engineered microbe platforms include PROT3EcT — EcN engineered to constitutively secrete TNFα-neutralizing nanobodies directly in the intestinal lumen, demonstrated to prevent chemically induced colitis in a single prophylactic dose (University of Bonn, 2022). Lactobacillus reuteri is engineered to secrete biologically active hIL-22 targeting intestinal inflammation. Lactococcus lactis GEN3013 is reported to inhibit tumor angiogenesis and augment oxaliplatin and PD-1 blockade efficacy in murine models. IBD-directed engineered bacteria are entirely at the preclinical stage in this dataset.
Still have questions about the engineered microbe therapeutic pipeline? Let PatSnap Eureka answer them for you.
Ask Eureka AI About This PipelineAccelerate Your Engineered Microbe R&D with AI-Powered Patent & Literature Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across oncology, IBD, and live biotherapeutics. Access the full engineered bacterium and oncolytic virus dataset — patents, literature, clinical signals, and assignee intelligence — in one AI-native workspace.
References
- Targeted Cancer Therapy Using Engineered Salmonella typhimurium — Chonnam National University (2016)
- Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in PDOX Murine Models — AntiCancer, Inc. (2019)
- Attenuated mutant strain of Salmonella Typhimurium lacking ZnuABC transporter — Istituto Superiore di Sanità (2015)
- Clostridium novyi-NT in cancer therapy — Johns Hopkins Medical Institutions (2016)
- Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo — University of Maastricht (2014)
- Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity — Synlogic, Inc. (2020)
- Probiotic neoantigen delivery vectors for precision cancer immunotherapy — Columbia University (2023)
- Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies — Columbia University (2019)
- Engineered bacteria recruit and orchestrate anti-tumor immunity — Columbia University (2022)
- Engineered E. coli for the targeted deposition of therapeutic payloads to sites of disease — University of Bonn (2022)
- In Situ Delivery and Production System (iDPS) of Anti-Cancer Molecules with Gene-Engineered Bifidobacterium — Shinshu University (2021)
- Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice — GIST (2021)
- Therapeutic potential of oncolytic Newcastle disease virus: a critical review — Hadassah Academic College (2015)
- Recombinant Immunomodulating Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma — Erasmus MC (2015)
- Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host — IOZK Cologne (2013)
- Oncolytic Adenoviruses in Gastrointestinal Cancers — Mayo Clinic Cancer Center (2018)
- Challenges and Pitfalls in the Engineering of Human Interleukin 22 Secreting Lactobacillus reuteri — Baylor College of Medicine (2020)
- Live Biotherapeutic Lactococcus lactis GEN3013 Enhances Antitumor Efficacy — GIST (2022)
- Impact of tumoral structure and bacterial species on growth and biodistribution of live bacterial therapeutics — RIKEN (2022)
- Programming the lifestyles of engineered bacteria for cancer therapy — Hefei National Research Center (2022)
- Controlled production of bacterial outer membrane vesicles in intestine as an effective tumor vaccine — National Center for Nanoscience and Technology (2021)
- National Institutes of Health (NIH) — Cancer Research Resources
- European Patent Office (EPO) — Biotech Patent Database
- World Health Organization (WHO) — Cancer Programme
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.